Scarica l'app Stockscreener
31.79
3.46%
-1.14
Dopo l'orario di chiusura:
31.79
Precedente Chiudi:
$32.93
Aprire:
$32.93
Volume 24 ore:
224.51K
Relative Volume:
0.59
Capitalizzazione di mercato:
$1.61B
Reddito:
$357.71M
Utile/perdita netta:
$-20.10M
Rapporto P/E:
-76.86
EPS:
-0.4136
Flusso di cassa netto:
$28.67M
1 W Prestazione:
+2.81%
1M Prestazione:
-2.60%
6M Prestazione:
-0.25%
1 anno Prestazione:
+7.54%
Intervallo 1D:
$31.65
$33.75
Intervallo di 1 settimana:
$30.76
$33.80
Portata 52W:
$23.15
$40.71
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
Nome
Immunocore Holdings Plc Adr
Settore
Industria
Telefono
01235 5430281
Indirizzo
90 PARK DRIVE, OXFORDSHIRE
Compare IMCR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
31.79 | 1.66B | 357.71M | -20.10M | 28.67M | -0.4136 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Aggiornamento | UBS | Sell → Buy |
| 2025-10-31 | Iniziato | Wells Fargo | Overweight |
| 2025-09-18 | Ripresa | Guggenheim | Neutral |
| 2025-08-25 | Ripresa | Jefferies | Buy |
| 2025-05-27 | Iniziato | Deutsche Bank | Buy |
| 2024-12-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-11-11 | Downgrade | Mizuho | Outperform → Neutral |
| 2024-10-24 | Iniziato | UBS | Sell |
| 2024-10-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-04-29 | Iniziato | Leerink Partners | Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-11-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-31 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-13 | Iniziato | Needham | Buy |
| 2023-08-16 | Iniziato | CapitalOne | Overweight |
| 2023-07-17 | Iniziato | Canaccord Genuity | Hold |
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2023-03-30 | Iniziato | Guggenheim | Buy |
| 2023-03-24 | Iniziato | Bryan Garnier | Buy |
| 2022-12-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-30 | Iniziato | Barclays | Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-08-08 | Iniziato | Cowen | Outperform |
| 2022-08-02 | Iniziato | BTIG Research | Buy |
| 2022-02-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-20 | Iniziato | Oppenheimer | Outperform |
| 2021-03-02 | Iniziato | Goldman | Neutral |
| 2021-03-02 | Iniziato | JP Morgan | Overweight |
| 2021-03-02 | Iniziato | Jefferies | Buy |
Mostra tutto
Immunocore Holdings Plc Adr Borsa (IMCR) Ultime notizie
Immunocore Holdings PLC Sponsored ADR $IMCR Stock Holdings Lifted by Candriam S.C.A. - MarketBeat
Immunocore Holdings PLC Sponsored ADR $IMCR Shares Sold by Principal Financial Group Inc. - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
GSK Gets EU Approval for Expanded Use of Nucala in COPD - Finviz
HC Wainwright Weighs in on Immunocore FY2030 Earnings - Defense World
Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates - Finviz
HC Wainwright Predicts Immunocore FY2030 Earnings - MarketBeat
NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View - Finviz
Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU - The Globe and Mail
Immunocore Holdings (IMCR) is One of the Best Small Cap Stocks Ready to Explode in 2026 - Finviz
Immunocore announces resignation of head of research and development By Investing.com - Investing.com South Africa
Immunocore announces resignation of head of research and development - Investing.com
Immunocore announces executive leadership changes in R&D - Investing.com
Immunocore announces R&D leadership evolution - GlobeNewswire Inc.
TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth - Finviz
BHC's Late-Stage Liver Cirrhosis Studies Fail, Stock Down - The Globe and Mail
CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study - Finviz
MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data - sharewise.com
Immunocore (IMCR) Soars 5.9%: Is Further Upside Left in the Stock? - Yahoo Finance
FDA Grants Breakthrough Therapy Tag to LLY's Ovarian Cancer Candidate - Finviz
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA - Finviz
BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises - Yahoo Finance
Immunocore (NASDAQ:IMCR) Upgraded at Zacks Research - Defense World
Immunocore (IMCR) upgraded to strong buy: Here's what you should know - MSN
Immunocore outlines 2026 strategy at J.P. Morgan conference - Investing.com
Immunocore outlines 2026 strategy at J.P. Morgan conference By Investing.com - Investing.com South Africa
Immunocore (IMCR) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Immunocore (NASDAQ:IMCR) Shares Gap UpWhat's Next? - MarketBeat
UBS assumes coverage on Immunocore stock with Buy rating, $55 target - Investing.com
UBS assumes coverage on Immunocore stock with Buy rating, $55 target By Investing.com - Investing.com South Africa
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Hudson Bay Capital Management LP Sells 49,382 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore Holdings PLC Sponsored ADR $IMCR Shares Bought by Frazier Life Sciences Management L.P. - MarketBeat
Bellevue Group AG Increases Stake in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Eschler Asset Management LLP Invests $1.26 Million in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
1,024,288 Shares in Immunocore Holdings PLC Sponsored ADR $IMCR Purchased by BVF Inc. IL - MarketBeat
Immunocore Holdings PLC Sponsored ADR $IMCR Stock Position Lowered by Armistice Capital LLC - MarketBeat
Immunocore Holdings plc (IMCR) Asserts Pipeline Development and Strong Commercial Performance - Finviz
Immunocore (NASDAQ:IMCR) Sets New 52-Week High – Here’s Why - Defense World
Immunocore (NASDAQ:IMCR) Reaches New 1-Year HighHere's What Happened - MarketBeat
Schroder Investment Management Group Boosts Stock Holdings in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore stock hits 52-week high at 40.71 USD By Investing.com - Investing.com India
Immunocore stock hits 52-week high at 40.71 USD - Investing.com
Immunocore (NASDAQ:IMCR) Shares Gap DownHere's What Happened - MarketBeat
Immunocore Holdings stock hits 52-week high at $40.53 - Investing.com
Immunocore Holdings stock hits 52-week high at $40.53 By Investing.com - Investing.com South Africa
Immunocore announces board and executive departures with no reported disagreements - Investing.com
Immunocore Holdings Plc Adr Azioni (IMCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immunocore Holdings Plc Adr Azioni (IMCR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Berman David M | HEAD OF R&D |
Dec 05 '25 |
Option Exercise |
17.46 |
572 |
9,987 |
572 |
| Berman David M | HEAD OF R&D |
Dec 04 '25 |
Sale |
40.26 |
31,341 |
1,261,789 |
0 |
| Berman David M | HEAD OF R&D |
Dec 05 '25 |
Sale |
40.14 |
572 |
22,960 |
0 |
| Berman David M | HEAD OF R&D |
Nov 26 '25 |
Option Exercise |
17.46 |
69,404 |
1,211,794 |
69,404 |
| Berman David M | HEAD OF R&D |
Nov 28 '25 |
Option Exercise |
17.46 |
5,521 |
96,397 |
5,521 |
| Berman David M | HEAD OF R&D |
Nov 26 '25 |
Sale |
40.12 |
69,404 |
2,784,488 |
0 |
| Berman David M | HEAD OF R&D |
Nov 28 '25 |
Sale |
40.09 |
5,521 |
221,337 |
0 |
| Berman David M | HEAD OF R&D |
Nov 25 '25 |
Option Exercise |
17.46 |
18,020 |
314,629 |
18,020 |
| Berman David M | HEAD OF R&D |
Nov 24 '25 |
Option Exercise |
17.46 |
100 |
1,746 |
100 |
| Berman David M | HEAD OF R&D |
Nov 25 '25 |
Sale |
40.03 |
18,020 |
721,341 |
0 |
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):